Last 25 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.22 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1.00 | 72.64 | 1.02 | 1.18 | 1.53 | 62.75 | — | 108.62 | 112.14 | 50.53 | 101.71 | 77.89 | 168.60 |
| — | +15.8% | — | -98.9% | -98.6% | +24.2% | — | +39.4% | -33.5% | -64.8% | -41.2% | -40.6% | -38.3% | |
| P/B Ratio | 0.28 | 0.38 | 0.39 | 0.32 | 0.28 | 6.55 | 7.16 | 6.88 | 6.66 | 10.23 | 7.54 | 6.14 | 6.80 |
| — | -94.2% | -94.6% | -95.4% | -95.7% | -36.0% | -5.0% | +12.1% | -2.0% | +54.0% | +32.4% | +4.4% | -7.1% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Bolt Biotherapeutics, Inc.'s operating margin was -29234.6% in Q1 2026, down 29010.4 pp QoQ and down 28243.2 pp YoY. The trailing four-quarter average of -7581.1% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin contracted 780.8% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 80.6% | -680.8% | 100.0% | 100.0% | 100.0% | 100.0% | — | 100.0% | 100.0% | 91.3% | -681.3% | -491.4% | -991.7% |
| — | -780.8% | — | 0.0% | 0.0% | +9.5% | — | +120.3% | +110.1% | +113.0% | +37.7% | +38.4% | +21.2% | |
| Operating Margin | -450.1% | -29234.6% | -224.2% | -355.1% | -510.5% | -991.4% | — | -1441.1% | -1772.3% | -324.1% | -946.2% | -719.3% | -1383.9% |
| — | -2848.8% | — | +75.4% | +71.2% | -205.9% | — | -100.4% | -28.1% | +67.9% | +36.5% | +32.0% | +16.4% | |
| Net Margin | -433.7% | -27861.5% | -265.2% | -329.4% | -474.6% | -903.4% | — | -1330.1% | -1662.4% | -205.0% | -857.0% | -643.1% | -1260.1% |
| — | -2983.9% | — | +75.2% | +71.5% | -340.7% | — | -106.8% | -31.9% | +78.0% | +39.5% | +37.6% | +22.6% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -79.7% | -31.3% | -22.6% | -20.1% | -20.0% | -21.2% | -24.7% | -19.2% | -22.3% | -10.0% | -14.9% | -12.0% | -12.0% |
| — | -47.3% | +8.2% | -4.8% | +10.4% | -113.0% | -66.0% | -59.9% | -85.2% | +3.4% | -33.7% | -9.5% | -16.0% | |
| ROA | -42.7% | -13.8% | -10.9% | -10.2% | -10.6% | -11.9% | -15.3% | -13.0% | -15.9% | -7.1% | -10.7% | -8.9% | -9.1% |
| — | -16.2% | +28.6% | +21.8% | +33.1% | -66.6% | -42.8% | -46.3% | -74.4% | +8.7% | -26.4% | -3.2% | -9.0% | |
| ROIC | -46.0% | -16.7% | -11.1% | -12.6% | -11.9% | -13.1% | -15.1% | -13.7% | -15.5% | -10.6% | -11.3% | -9.4% | -9.4% |
| — | -27.1% | +26.3% | +8.0% | +23.8% | -23.8% | -33.2% | -46.2% | -64.7% | -34.4% | -38.3% | -14.8% | -13.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 11.9% YoY to 3.51x, strengthening the short-term liquidity position. Debt/Equity has risen for 12 consecutive quarters, indicating increasing financial leverage that investors should watch closely.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.87 | 1.13 | 0.87 | 0.73 | 0.62 | 0.53 | 0.44 | 0.25 | 0.22 | 0.19 | 0.18 | 0.16 | 0.15 |
| — | +113.2% | +96.5% | +191.2% | +183.0% | +181.0% | +145.8% | +55.2% | +45.6% | +34.3% | +36.0% | +31.9% | +37.2% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.59 | 3.51 | 3.59 | 3.57 | 3.11 | 3.13 | 3.20 | 3.16 | 4.28 | 5.68 | 5.17 | 6.69 | 7.42 |
| — | +11.9% | +11.9% | +13.1% | -27.3% | -44.9% | -38.0% | -52.8% | -42.3% | -29.8% | -30.8% | -7.5% | -23.8% | |
| Quick Ratio | 3.59 | 3.51 | 3.59 | 3.57 | 3.11 | 3.13 | 3.20 | 3.16 | 4.28 | 5.68 | 5.17 | 6.69 | 7.42 |
| — | +11.9% | +11.9% | +13.1% | -27.3% | -44.9% | -38.0% | -52.8% | -42.3% | -29.8% | -30.8% | -7.5% | -23.8% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 25 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BOLT stock.
Bolt Biotherapeutics, Inc.'s current P/E is -0.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Bolt Biotherapeutics, Inc.'s current operating margin is -450.1%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Bolt Biotherapeutics, Inc.'s business trajectory between earnings reports.